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Background: We analyzed the significance of class III beta-tubulin
(TUBB3) expression in curatively resected non-small cell lung
cancer as a prognostic marker along with previously reported exci-
sion repair cross complementation group 1 (ERCC1).
Methods: One hundred and thirty-six consecutive patients were
included in this retrospective study. Patients who received adjuvant
chemotherapy were excluded. We used immunohistochemistry to
evaluate TUBB3 and ERCC1 expression on tissue microarray in
duplicate. Semiquantitative H score was used for the scoring of
tumor staining.
Results: Sixty percent of patients had stage I disease, 17% stage II,
18% stage IIIA, and 5% stage IIIB. TUBB3 H score showed
bimodal distribution with the minimum at the value of 4, which was
used as a cutoff value for determination of TUBB3 positivity.
TUBB3 was expressed in 60 patients (44%). Patients with a positive
TUBB3 expression survived shorter than did the patients with a
negative expression (5-year overall survival [OS] rate was 40%
versus 61%; p  0.005/5-year disease-free survival rate was 34%
versus 55%; p  0.024). ERCC1 expression showed tendency for
prolonged OS without reaching statistical significance. A multivar-
iate analysis that incorporated covariates including TUBB3 expres-
sion, age, stage, EGFR mutation status, histology, and ERCC1
expression showed that TUBB3 was an independent unfavorable
prognostic factor for OS (hazard ratio 2.083; p  0.008) and relapse
free survival (hazard ratio 1.978; p  0.020).
Conclusions: TUBB3 expression is an independent unfavorable
prognostic marker in patients with curatively resected non-small cell
lung cancer who did not receive adjuvant chemotherapy.
Key Words: Non-small cell lung cancer, Prognosis, Class III
beta-tubulin.
(J Thorac Oncol. 2010;5: 320–325)
No single strong predictive and prognostic molecularmarker like p53 in head and neck squamous cell carci-
noma has been discovered in non-small cell lung cancer
(NSCLC), despite of vigorous efforts. However, recent stud-
ies report promising results of a molecule excision repair
cross complementation group 1 (ERCC1). ERCC1 has been
investigated along with platinum use in NSCLC. First anal-
ysis of ERCC1 expression emphasized chemotherapeutic
resistance of this molecule, but analysis of ERCC1 in various
settings suggested that ERCC1 expression is not mere a
predictive marker for chemotherapy resistance but also may
serve as a prognostic marker.1–5 We also reported previously
that ERCC1 expression may be a prognostic marker in
NSCLC.6 The mechanism of platinum resistance of ERCC1
is fairly well established and thus is ERCC1 expression as a
predictive marker for platinum-based chemotherapy, but un-
derlying mechanism possibly conveying good prognosis is
not defined yet.
Along with cisplatin, taxanes, and vinorelbine are also
actively used in NSCLC.7,8 These two antitubulin agents
draw interest in molecules called tubulin isofamilies. Micro-
tubules are complex polymers consisting of tubulin dimers
(containing one -tubulin and one -tubulin molecule) and a
variety of microtubule-associated proteins.9 In humans, there
are a number of tubulin isotypes, which mainly differ in their
C-terminal sequence.10 Dumontet et al.9 studied immunohis-
tochemical expression of these tubulin isotypes in NSCLC
and found that class III -tubulin (TUBB3) among them is
expressed in a proportion and related to clinical outcome. In
recent 5 years after the study by Dumontet, TUBB3 is
actively investigated and now it is recognized to have a role
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in resistance to antitubulin agents. In fact, TUBB3 is ex-
pressed in high levels in lung cancer cell lines, and high
levels of TUBB3 expression are associated with paclitaxel
and docetaxel resistance in vitro.11–13 Clinical researches also
revealed that TUBB3 expression is a predictive marker for
chemotherapy response in NSCLC.14–17
However, the role of TUBB3 expression as a prognos-
tic marker in NSCLC is not well reported. Recently, Seve et
al.18 performed posthoc translational research of JBR10 study
where half of the patients received adjuvant chemotherapy
consisted of vinorelbine and cisplatin. Fifty-five percent of
patients enrolled in JBR10 were evaluable for TUBB3 ex-
pression, and the study showed that TUBB3 expression is
a poor prognostic marker. TUBB3 expression has been re-
ported to be a prognostic marker in the other cancers.14,19
However, whether the expression of TUBB3 contributes to a
aggressive behavior of the tumor per se or to a vinca alkaloid
and taxane specific resistance is an unanswered issue.20 Also,
referring from the case of ERCC1 expression, it is worth-
while to investigate the role of TUBB3 expression in various
settings to clarify the exact meaning of TUBB3 expression.
So, we analyzed the clinical significance of TUBB3
expression in curatively resected NSCLC not receiving adju-
vant chemotherapy. We also combined our previous results
regarding ERCC1 expression in subgroup of this study pop-
ulation for comparison. Our aim is to identify the role of
TUBB3 expression as prognostic marker along with ERCC1
expression.
PATIENTS AND METHODS
Patients and Treatment Plan
A cohort of consecutive 136 patients who received
curative surgery for NSCLC at Seoul National University
Hospital between January 1997 and December 1998, and for
whom a formalin-fixed paraffin-embedded sample adequate
for analysis was available, were included in this retrospective
study. Patients with adenocarcinoma, squamous cell carci-
noma, adenosquamous carcinoma, bronchioloalveolar carci-
noma, mucoepidermoid carcinoma, carcinoid tumor, and
large cell carcinoma were eligible, whereas patients with
small cell lung cancer were excluded. All patients received
curative resection without microscopic residual tumors. We
included patients who received adjuvant radiotherapy,
whereas excluded patients who received adjuvant chemother-
apy. Subgroup of 130 patients among the study population
were analyzed for ERCC1 expression previously, and the
results are reported elsewhere.6
Data regarding patient demographics, clinicopathologic
characteristics including gender, age, smoking history, histo-
logic subtype, pathologic stage, relapse free survival (RFS),
and overall survival (OS) were obtained by medical record
review. RFS was defined as a period from curative resection
to documentation of disease recurrence. OS was calculated
from diagnosis to death from any cause.
The study protocol was reviewed and approved by the
institutional review board of Seoul National University Hos-
pital. The recommendations of the Declaration of Helsinki for
biomedical research involving human subjects were also
followed.
Tissue Microarray and Immunohistochemical
Staining for TUBB3 and ERCC1
Tumor specimen of 130 patients among this study
population were tested for ERCC1 with immunohistochem-
istry (IHC) previously, hence, the IHC method for ERCC1 is
described elsewhere.6 Slides of tumor samples stained with
hematoxylin and eosin were independently reviewed by two
pathologists (B.J. and D.H.C.), and representative areas were
marked. Core tissue biopsy specimens (2 m in diameter) in
duplicate were obtained from individual paraffin-embedded
samples (donor blocks) and arranged in a new recipient
paraffin block (tissue array block) using trephine apparatus
(SuperBioChips, Seoul, Korea). Each tissue array block con-
tained upto 60 specimens, which allowed all 272 specimens
(duplicate specimens of 136 cases) to be contained in six
array blocks. Sections (4 m) from formalin-fixed paraffin-
blocks were analyzed for TUBB3. Each paraffin section was
dewaxed followed by antigen retrieval.
IHC for TUBB3 was performed as previously de-
scribed.21,22 Antigen retrieval was performed using 0.01 M
pH 6.0 buffer and microwave for 15 minutes. Then slides
were incubated with mouse monoclonal antibody for TUBB3
(Covance, clone TUJ1, 1:1200 Princeton, NJ). The antibodies
use and subsequent steps were performed according to the
manufacturer’s instructions. Antibody binding was detected
by means of detection kit of Ultravision (Thermo Scientific,
Erembodegem, Belgium). Mayer’s hematoxylin was used as
the counter stain. Various normal and cancer tissue microar-
ray blocks were included as external controls.
Microscopic Analysis
Microscopic analysis method for ERCC1 expression is
described elsewhere.6 Tumor staining was assessed by two
trained pathologist (B.J. and D.H.C.) who had no knowledge
of patient’s clinical data under the light microscope at 200
and 400 magnifications. As in ERCC1, semiquantitative H
score was used for evaluation of TUBB3 expression. H score
was defined as a product of TUBB3 staining intensity and
area proportion score.23–25 Briefly, TUBB3 tumor staining
(cytoplasm) intensity was graded on a scale of 0 to 2 using
adjacent nonmalignant cells as a reference. The percentage of
positive tumor cell was evaluated, and a area proportion score
was attributed (0 if 0%, 0.5 if 1–9%, 1 if 10–24%, 2 if
25–49%, 3 if 50–74%, and 4 if 75%). This proportion
score was then multiplied by the staining intensity to obtain
a final semiquantitative H score with a range of 0 to 8.
Statistical Analysis
The variables included for analysis in this study were age,
gender, smoking history, stage, histology, EGFR mutation sta-
tus, ERCC1 expression status, TUBB3 expression status, RFS,
and OS. Statistical analysis of 2  2 contingency tables of
categorical variables were performed using Pearson’s 2 test or
Fisher exact test, as appropriate. Median durations of RFS
and OS were calculated using the Kaplan-Meier method and
comparisons between groups were made using log-rank tests.
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Five-year RFS and OS rate was calculated using life table
method. Multivariate analysis was performed using Cox propor-
tional hazard regression model for RFS and OS. Factors with
p values less than 0.10 in univariate analysis were examined
with proportional hazard regression model. All statistical tests
were two sided, with significance defined as p less than 0.05. All
analysis was performed using SPSS for Windows Version 12.0
(SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
This study included 101 men and 35 women with a
median age of 61 years. Ninety-four patients (69%) had a
history of smoking. Eighty-one patients (60%) had stage I, 23
patients (17%) had stage II, and 32 patients (23%) had stage
III. For histology, this study included 39 patients with ade-
nocarcinoma (29%), 68 patients with squamous cell carci-
noma (50%), 14 patients with bronchioloalveolar carcinoma
(10%), 8 adenosquamous carcinoma (6%), 2 mucoepider-
moid carcinoma (2%), 4 large cell carcinoma (3%), and 1
carcinoids (1%). Adjuvant radiotherapy was given to 21
patients (15%). These results are summarized in Table 1.
TUBB3 and ERCC1 Expression by IHC
The expression of TUBB3 and ERCC1 were evaluable
in 136 and 130 patients, respectively (Figure 1). TUBB3 H
score showed bimodal distribution with the minimum at the
value of 4, which was used as a cutoff value for determination
of TUBB3 positivity (Figure 2). Sixty patients (44%) had
positive TUBB3 expression. Eighty patients showed positiv-
ity and 50 patients showed negativity for ERCC1 expression.
TUBB3 expression was more frequently observed in
stage III patients than stage I and II patients (p  0.047).
TUBB3 was more frequently expressed in adenocarcinoma
than in squamous cell carcinoma (67% for adenocarcinoma
and 35% for others, p  0.001). Age, gender, and smoking
history were not associated with TUBB3 expression. ERCC1
expression was not associated with TUBB3 expression (p 
0.595). These results are summarized in Table 2.
Correlations Between RFS, OS, and Expression
of TUBB3 and ERCC1
During median follow-up of 113 months, 67 patients
experienced relapse, and 76 patients died. Median RFS was 41.6
months and RFS was not different according to gender, smoking
history, and histology. Pathologic staging correlated well with
RFS (p  0.001). ERCC1 expression did not influence RFS
(Median RFS 54 months versus 32 months for ERCC1 positive
and negative patients, respectively, p  0.526). Median RFS
was significantly shorter in patients with TUBB3 expression (37
months versus not reached, p  0.024) (Figure 3). Five-year
RFS rate was 34% in TUBB3 positive patients, while 55% in
TUBB3 negative patients. In multivariate analysis considering
stage, histology, EGFR mutation status, and TUBB3 expression
status, TUBB3 expression was related to shorter RFS with
hazard ratio of 1.978 (p  0.020) (Table 3).
Median OS was 74 months, and OS was not different
according to gender, smoking history, and histology. Pathologic
FIGURE 1. Representative examples
of TUBB3 immunostains (200) A,
TUBB3 is strongly stained in cyto-
plasm. H score is 8. B, TUBB3 is
barely stained. H score is 0.
TABLE 1. Baseline Characteristics of 136 Patients with
Curatively Resected NSCLC
No. of Patients (%) Number
Age (median, range) 61 (33–80)
Gender
Male 101 (74)
Female 35 (26)
Smoking history
Yes 94 (69)
No 42 (31)
Pathologic stage
Ia 24 (18)
Ib 57 (42)
IIa 8 (6)
IIb 15 (11)
IIIa 25 (18)
IIIb 7 (5)
Pathology
Adenocarcinoma 39 (29)
Squamous cell carcinoma 68 (50)
Bronchioloalveolar carcinoma 14 (10)
Adenosquamous 8 (6)
Mucoepidermoid carcinoma 2 (2)
Large cell carcinoma 4 (3)
Carcinoid 1 (1)
Adjuvant radiotherapy
Yes 21 (15)
No 115 (85)
NSCLC, non-small cell lung cancer.
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staging predicted OS well (p  0.001). ERCC1 expression
showed tendency for prolonged median OS (108 months versus
47 months, p  0.064). On the other hand, TUBB3 positive
patients survived the shorter compared with the TUBB3 nega-
tive patients (median OS 54 months versus not reached, p 
0.005) (Figure 3). Five-year survival rate was 40 and 61% for
TUBB3 positive and negative patients, respectively. In multi-
variate analysis considering age, stage, histology, EGFR muta-
tion status, ERCC1 expression, and TUBB3 expression, TUBB3
expression was a poor prognostic factor for OS with hazard ratio
of 2.083 (p  0.008) (Table 3).
We performed subgroup analysis according to ERCC1
expression status. TUBB3 expression was related to short
RFS (median RFS 40 months versus not reached, p  0.038)
and short OS (median OS 56 months versus not reached, p 
0.016) in ERCC1 positive patients (n  80). However, for
ERCC1 negative patients (n  50), TUBB3 expression did
not influence either RFS (median RFS 28 months versus 45
months, p  0.418) or OS (median OS 50 months versus 41
months, p  0.276). In subgroup analysis considering histol-
ogy, TUBB3 expression was a poor prognostic marker for
RFS and OS in patients with nonadenocarcinoma histology
(p  0.038 and 0.022, respectively). However, for patients
with adenocarcinoma, TUBB3 was not a prognostic factor in
terms of either RFS or OS.
DISCUSSION
In this study, we showed that TUBB3 expression is a
strong prognostic marker in terms of RFS and OS in curatively
resected patients with NSCLC who did not receive adjuvant
chemotherapy. This result convinces the conjecture of Seve et al
and Seve and Dumontet18,20 that TUBB3 expression is a prog-
nostic marker in NSCLC. Recent data also consistently suggest
that TUBB3 expression is related to aggressive tumor behavior
in various cancers,14,19,26,27 and our result also showed that
TUBB3 was more frequently expressed in advanced stage
NSCLC. However, the underlying mechanism how TUBB3
expression conveys poor prognosis is unknown and yet to be
elucidated by in vitro research.
Comparison of TUBB3 expression with ERCC1 expres-
sion as a pure prognostic marker is interesting. ERCC1 expres-
sion has been implicated to be a prognostic marker in some
studies, but the conflicting results exists with regard to the pure
prognostic role of ERCC1 expression.28 And the conflict is also
reflected in our experience. We reported the prognostic value of
ERCC1 expression in resected NSCLC previously.6 In the re-
port, ERCC1 expression had good prognostic impact in terms of
OS in univariate analysis (p 0.046) but lost its significance in
multivariate analysis (p 0.051). In this study, ERCC1 expres-
FIGURE 2. Histogram showing TUBB3 H score distribution
of 136 patients TUBB3 H score shows bimodal distribution
with minimum value of 4, which is used as a cutoff value.
TABLE 2. Characteristics of Patients and Tumors According
to TUBB3 Expression Status in 136 Patients
Characteristics
TUBB3()
H Score >4
(n  60)
TUBB3()
H Score <4
(n  76) p
Age
60 yr 31 43 0.568
60 yr 29 33
Gender
Male 42 59 0.312
Female 18 17
Smoking
Yes 38 56 0.195
No 22 20
Pathology
Adenocarcinoma 26 13 0.003
Squamous cell carcinoma 19 49
Bronchioloalveolar carcinoma 5 9
Adenosquamous 5 3
Mucoepidermoid carcinoma 1 1
Large cell carcinoma 3 1
Carcinoid 1 0
Pathology modified
Adenocarcinoma 26 13 0.001
Nonadenocarcinoma 34 63
Stage
I 32 49 0.139
II 9 14
III 19 13
Stage modified
I and II 19 63 0.047
III 41 13
ERCC1a
Negative 23 27 0.595
Positive 33 47
a Six patients did not have information on ERCC1 status.
TUBB3, class III beta-tubulin.
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sion lost its prognostic value in terms of OS even in univariate
analysis, and we assume that this is attributable to lengthened
follow-up duration with additional relapse and death since last
study. To summarize, although ERCC1 expression is a strong
predictive marker for platinum based chemotherapy, it may not
serve as a robust pure prognostic marker. In this sense, strong
prognostic information carried by TUBB3 expression in this
study is valuable.
FIGURE 3. RFS and OS according to TUBB3 and
ERCC1 expression status TUBB3 expression (dotted
line) was related to short RFS and OS (A and B). On
the other hand, ERCC1 expression (dotted line) did
not show significant prognostic impact in terms of
either RFS (C) or OS (D).
TABLE 3. Hazard Ratio (HR) and p Value of Age, Stage, Histology, EGFR Mutation Status, TUBB3 Expression, and ERCC1
Expression for RFS and OS in Multivariate Analysis
Relapse-Free Survival Overall Survival
HR
95% Confidence Interval
HR
95% Confidence Interval
Lower Upper p Lower Upper p
Age 1.005 0.972 1.038 0.780
Stage
Ia 1 0.001 1 0.002
Ib 0.534 0.243 1.171 0.814 0.360 1.839
IIa 0.807 0.247 2.640 1.072 0.321 3.579
IIb 2.424 0.936 6.280 2.825 1.081 7.381
IIIa 4.359 1.983 9.583 2.868 1.240 6.630
IIIb 1.778 0.598 5.282 2.329 0.738 7.351
Histology
Adenocarcinoma 1 0.455 1 0.423
SCC 1.660 0.833 3.309 1.839 0.914 3.698
BAC 1.761 0.686 4.523 1.202 0.448 3.223
Adenosquamous 1.488 0.525 4.217 1.526 0.573 4.066
MEC 6.437 1.368 30.276
Large cell carcinoma 3.682 0.992 13.661 2.269 0.609 8.445
Carcinoid 18.814 2.191 161.570
EGFR mutation
Negative 1 0.435 1 0.542
Positive 1.249 0.715 2.179 1.194 0.674 2.115
TUBB3
Negative 1 0.020 1 0.008
Positive 1.978 1.116 3.505 2.083 1.215 3.571
ERCC1
Negative 1 0.167
Positive 0.666 0.374 1.185
SCC, squamous cell carcinoma; BAC, bronchioloalveolar carcinoma; MEC, mucoepidermoid carcinoma.
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On the other hand, as recently benefit of adjuvant
chemotherapy in NSCLC has been proved,29 it is important to
select patient population, which may benefit from specific
regimen. ERCC1 expression is a single important molecule
influencing patient selection at the present. However, we
expect TUBB3 expression would also serve as an important
molecule for selection of adjuvant chemotherapy in a near
future because it conveys prognostic and predictive informa-
tion30,31 at the same time.
In addition, subgroup analysis also showed interesting
results. First, impact of TUBB3 expression was different accord-
ing to ERCC1 expression status, although statistically significant
interaction between ERCC1 and TUBB3 expression was not
shown. We expect this phenomenon could also influence the
decision of chemotherapy regimen based on the molecular
profiling in the future. However, the biologic explanation for this
phenomenon is lacking and is to be clarified. Second, in sub-
group analysis based on histology, TUBB3 was expressed more
frequently in adenocarcinoma as in the previous studies.14,15 On
the other hand, the prognostic impact of TUBB3 expression was
confined to nonadenocarcinoma histology. Whether the impli-
cation of TUBB3 expression really differs according to histol-
ogy needs to be verified. Considering that 39 patients had
adenocarcinoma in our study, there is a chance that impact of
TUBB3 expression lost statistical significance in adenocarci-
noma histology because of the small number of patients.
In conclusion, TUBB3 expression is a strong poor
prognostic marker, and it should be considered in the treat-
ment of NSCLC. It may serve as a useful marker for deter-
mination of adjuvant chemotherapy in the future along with
ERCC1 expression.
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